Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is demonstrating strong potential for growth and success in the near future due to their innovative product offerings and strategic partnerships in the healthcare industry. Their financial losses are being offset by recent fundraising and the potential for Medicare coverage, and they have multiple key drivers for growth such as expanding into the LBM market and increasing sales rep efficiency. While there are potential risks to their rating and price target, Lucid's positive reception in the medical community and potential for increased collections make it a promising investment opportunity.

Bears say

Lucid Diagnostics is facing challenges in commercializing its products due to a small sales force and slow progress in expanding test volumes. The delay in Medicare coverage is a major concern, as it could limit revenue generation and have an adverse effect on the business. Additionally, while the company's products have potential, there are still risks related to reimbursement and commercial execution. With a relatively low price target of $2.50, the negative outlook is based on the company's current operating level and potential for delays in revenue generation.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.